This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Hanly, J.G. Articles by Jones, E. Search for Related Content PubMed PubMed Citation Articles by Hanly, J.G. Articles by Jones, E. Social Bookmarking                         What's this?

Immunomodulating effects of synchronised plasmapheresis and intravenous bolus cyclophosphamide in systemic lupus erythematosus

Division of Rheumatology, Department of Medicine, Suite 310, Bethune Building, Victoria General Hospital, Halifax, Nova Scotia

C. Hong

Division of Rheumatology, Department of Medicine, Suite 310, Bethune Building, Victoria General Hospital, Halifax, Nova Scotia

E. Zayed

Division of Hematology, Department of Pathology, Victoria General Hospital and Dalhousie University, Halifax, Nova Scotia, Canada

J.V. Jones

Division of Rheumatology, Department of Medicine, Suite 310, Bethune Building, Victoria General Hospital, Halifax, Nova Scotia

E. Jones

Division of Rheumatology, Department of Medicine, Suite 310, Bethune Building, Victoria General Hospital, Halifax, Nova Scotia

Recent studies have suggested that synchronised plasmapheresis and intravenous pulse cyclophosphamide therapy reduce disease activity in SLE patients. The aim of the present study was to examine the immunomodulating effects of this therapy and compare it with changes seen with cyclophosphamide alone. Four patients with active SLE were studied. Two were treated with synchronised therapy and two received cyclophosphamide only for up to 26 weeks. Disease activity was measured by the SLE disease activity index (SLEDAI). Immunological studies were performed immediately prior to each treatment. Patients in both treatment groups improved as reflected by a fall in mean SLEDAI scores: synchronised therapy 33.5 to 11; cyclophosphamide only 13.5 to 4.5. Following synchronised therapy only there was a prompt and sustained increase in the mean percentage of CD8 ⁺ cells (20.8 to 54.8) which resulted in a fall in the CD4:CD8 ratio (1.95 to 0.62). With both treatment modalities there was a fall in the proportion of CD20⁺ cells (B lymphocytes) (synchronised therapy 10.5 to 3.2; cyclophosphamide only 5.6 to 2.2). However, only synchronised therapy resulted in a fall in the in vitro production of immunoglobulins which was unchanged or increased following cyclophosphamide alone. These results suggest that although both treatment modalities are efficacious in the treatment of active SLE they produce different immunomodulatory effects. Thus, both therapies reduce the number of circulating B lymphocytes whereas synchronised therapy also modifies cellular immunity by promoting the emergence of a phenotypic suppressor T lymphocyte population.

Key Words: cyclophosphamide • plasmapheresis • immunomodulation

Lupus, Vol. 4, No. 6, 457-463 (1995)
DOI: 10.1177/096120339500400607


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G G Illei and J H Klippel Novel approaches in the treatment of lupus nephritis Lupus, November 1, 1998; 7(9): 644 - 648. [Abstract] [PDF]